EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Calmodulin kinase-like vesicle-associated protein (CAMKV) autoimmune encephalitis: Neurological & oncological accompaniments, treatments & outcomes

Diana Anissian, Michael Gilligan, Connie E Lesnick, Yong Guo, Binxia Yang, Paulina Vargas, Alise K Carlson, Christopher J Hogge, Swantje Mindorf, Anastasia Zekeridou, Divyanshu Dubey, Andrew McKeon

Translational Oncology · 2026-12 · 74 · 103090

DOI: 10.1016/j.tranon.2026.103090 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Translational Oncology, 2026-12. Verfasst von Diana Anissian und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Institute of Neurological Disorders and Stroke.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND & OBJECTIVES: We previously reported CAMKV-IgG paraneoplastic encephalitis accompanying uterine and neuroendocrine-lineage carcinomas. Here, we describe 7 new cases (12 total) and report CSF cytokine/chemokine profiles and coexisting antibody frequency. METHODS: Patient samples demonstrating the CAMKV-specific murine tissue-based indirect immunofluorescence assay (TIIFA) staining pattern were tested by protein microarray and confirmed CAMKV-specific cell-based assay. CSF cytokines/chemokines were analyzed in 4 patients. RESULTS: Median symptom-onset age was 69 years (range 53-79); 8/12 were women. Common manifestations included altered mental status (7/12), hyperkinetic movements (6/12), seizures (5/12), psychiatric, and insomnia (4/12 each). Five patients had coexisting antibodies: tripartite motif-containing protein-9 (3), N-methyl-D-aspartate receptor (2), antineuronal nuclear antibody-type-1 (ANNA-1) and γ-aminobutyric acid B receptor (1 each). All 12 had cancer, including adenocarcinoma (6/12; uterine 4, lung 1, prostate 1), lymphoma (Hodgkin and non-Hodgkin), or other carcinoma (urothelial, Merkel cell, hepatocellular, and poorly differentiated (1 each). All 3 available cancers (uterine, 2; prostate adenocarcinoma, 1) were immunohistochemistry positive for CAMKV. 6/8 had CSF lymphocytic pleocytosis. MRIs revealed mesial temporal and basal ganglia T2 hyperintensities in 6/10 and 5/10, respectively. Among 7 immunotherapy-treated patients, 6 improved initially, although 5/7 with follow-up died from cancer. CSF IL-13 and GM-CSF were significantly elevated compared with non-inflammatory controls (FDR-adjusted P < 0.05). Four of 42 ANNA-1 positive samples with coexisting synaptic TIIFA staining were CAMKV-IgG positive. DISCUSSION: CAMKV-IgG is a paraneoplastic encephalitis autoantibody associated with diverse cancers. Neurologic improvement with immunotherapy is frequent, but prognosis is driven by cancer outcomes. Elevated IL-13 may indicate metastatic risk.

Schlagwörter

Stichwörter der Autor:innen

Autoimmune encephalitisCAMKVImmune checkpoint inhibitorsParaneoplastic neurological syndrome

Autor:innen und Institutionen

  • Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
  • Department of Neurology, Mayo Clinic, Rochester, MN, USA.
  • Mellen Center for Multiple Sclerosis Treatment and Research, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA.
  • Department of Neurology, Walter Reed National Military Medical Center (WRNMMC), Bethesda, MD 20814, USA.
  • Institute for Experimental Immunology, affiliated to EUROIMMUN Medizinische Labordiagnostika AG, Lübeck, Germany.
  • Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA; Department of Neurology, Mayo Clinic, Rochester, MN, USA.

Förderung

  • National Institute of Neurological Disorders and Stroke

Zitieren

APA

Anissian, D., Gilligan, M., Lesnick, C. E., Guo, Y., Yang, B., Vargas, P., Carlson, A. K., Hogge, C. J., Mindorf, S., Zekeridou, A., Dubey, D., & McKeon, A. (2026). Calmodulin kinase-like vesicle-associated protein (CAMKV) autoimmune encephalitis: Neurological & oncological accompaniments, treatments & outcomes. Translational Oncology, 74, 103090. https://doi.org/10.1016/j.tranon.2026.103090

Vancouver

Anissian D, Gilligan M, Lesnick CE, Guo Y, Yang B, Vargas P, et al. Calmodulin kinase-like vesicle-associated protein (CAMKV) autoimmune encephalitis: Neurological & oncological accompaniments, treatments & outcomes. Translational Oncology. 2026;74:103090. doi:10.1016/j.tranon.2026.103090

BibTeX
@article{Anissian2026,
  author = {Anissian, Diana and Gilligan, Michael and Lesnick, Connie E and Guo, Yong and Yang, Binxia and Vargas, Paulina and Carlson, Alise K and Hogge, Christopher J and Mindorf, Swantje and Zekeridou, Anastasia and Dubey, Divyanshu and McKeon, Andrew},
  title = {Calmodulin kinase-like vesicle-associated protein (CAMKV) autoimmune encephalitis: Neurological & oncological accompaniments, treatments & outcomes},
  journal = {Translational Oncology},
  year = {2026},
  volume = {74},
  pages = {103090},
  doi = {10.1016/j.tranon.2026.103090}
}
Kostenlos starten →